1,721,186 research outputs found
Risultati preliminari dello studio sulla genetica della malattia di Alzheimer in Sardegna
No full textDetermination of protein-incorporated methylated arginine reference values in healthy subjects whole blood and evaluation of factors affecting protein methylation
No full text
Intraocular pressure in Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
No full textPurpose: Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is one of the most common human genetic abnormalities, with a high prevalence in Sardinia, Italy, where the reported rates range from 10% to 15%. Hemizygous males have totally deficient erythrocytes. We are unaware of any previous report investigating intraocular pressure (IOP) in G6PD deficiency. The purpose of this study was to assess IOP in G6PD-deficient and G6PD-normal Sardinian men and ascertain whether there are significant differences between the two groups.
Methods: IOP was measured by applanation tonometry in 104 G6PD-deficient and 104 age-matched G6PD-normal men. The Student t test was used to assess differences in IOP values between the two groups.
Results: Mean IOP was 13.94 ± 2.62 mm Hg in G6PD-deficient men and 14.29 ± 2.84 mm Hg in G6PD-normal men, a not statistically significant result (P = 0.096).
Conclusions: Results suggest that men with G6PD deficiency do not have a higher risk of increased IOP
Sodium glycylglycine as effective electrolyte run buffer for ascorbic and uric acid separation by CZE: a comparison with two other CE assays
No full textSerum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression
No full textAlterations in cardiac and renal biomarkers have been reported in coronavirus disease 19 (COVID-19). We conducted a systematic review and meta-analysis to investigate serum concentrations of hydroxybutyrate dehydrogenase (HBDH), a combined marker of myocardial and renal injury, in hospitalized COVID-19 patients with different disease severity and survival status. We searched PubMed, Web of Science and Scopus, between December 2019 and April 2021, for studies reporting HBDH in COVID-19. Risk of bias was assessed using the Newcastle–Ottawa scale, publication bias was assessed with the Begg’s and Egger’s tests, and certainty of evidence was assessed using GRADE. In 22 studies in 15,019 COVID-19 patients, serum HBDH concentrations on admission were significantly higher in patients with high disease severity or non-survivor status when compared to patients with low severity or survivor status (standardized mean difference, SMD = 0.90, 95% CI 0.74 to 1.07, p < 0.001; moderate certainty of evidence). Extreme between-study heterogeneity was observed (I2 = 93.5%, p < 0.001). Sensitivity analysis, performed by sequentially removing each study and re-assessing the pooled estimates, showed that the magnitude and the direction of the effect size were not substantially modified. A significant publication bias was observed. In meta-regression, the SMD of HBDH concentrations was significantly associated with markers of inflammation, sepsis, liver damage, non-specific tissue damage, myocardial injury, and renal function. Higher HBDH concentrations were significantly associated with higher COVID-19 severity and mortality. This biomarker of cardiac and renal injury might be useful for risk stratification in COVID-19. (PROSPERO registration number: CRD42021258123)
Simultaneous determination of citrulline and arginine in human blood plasma by capillary electrophoresis with ultraviolet absorption detection
No full textA new capillary electrophoresis method to measure human blood plasma arginine and
citrulline levels in a single run without derivatization was established. After adding homoarginine
as internal standard, plasma proteins were removed by a 90:10 v/v acetonitrile/ammonia
mixture. Arginine and citrulline were detected by an ultraviolet detector at
190 nm and separated in 11.65 and 20.43 min, respectively, by using a 75 mmol/L Tris
phosphate solution at pH 1.2 as a background electrolyte. Limits of detection were 0.8 and
5 mol/L for arginine and citrulline, respectively. Precision tests indicated a good repeatability
of migration times and of peak area both for citrulline (CV% = 0.82 and 3.19) and
arginine (CV% = 0.65 and 2.79). The CV% for intra- and interassay tests were, respectively,
1.84 and 3.23 for citrulline and 1.25 and 1.50 for arginine. Mean recovery was 101.5 and
98.5% for citrulline and arginine, respectively. The performance of the developed method
was assessed by measuring plasma arginine levels in 52 subjects and the data were compared
with those obtained by our previous assay. The new method was then applied to assess
plasma citrulline and arginine in ten chronic kidney disease patients under hypolipidemic
therapy with statin
- …
